---
title: "Target of the Month: Interleukin-17"
description: "Target of the month: Interleukin-17 or IL17"
image: https://insights.accencio.com/hubfs/accencio-target-of-the-month-il17.jpg
---

[Skip to content](https://insights.accencio.com/blog/target-of-the-month-interleukin-17#main-content)

[![](https://insights.accencio.com/hs-fs/hubfs/ACCENCIO_Logo_final%20with%20R-2.png?width=3000&height=783&name=ACCENCIO_Logo_final%20with%20R-2.png)](https://www.accencio.com/)

- [About](https://www.accencio.com/about)
- [Insights](https://insights.accencio.com/blog)
- [Contact Us](https://www.accencio.com/inquiries)
- [Login](https://portal.accencio.com/session/loginone)

Open main navigation

Close main navigation

- [About](https://www.accencio.com/about)
- [Insights](https://insights.accencio.com/blog)
- [Contact Us](https://www.accencio.com/inquiries)
- [Login](https://portal.accencio.com/session/loginone)

[All posts](https://insights.accencio.com/blog/all)

 February 4, 2025

# Target of the Month: Interleukin-17

 By   Kevin Brogle (Ph.D.)  ·   1 minute read

## [![Interleukin-17 (IL17)](https://insights.accencio.com/hs-fs/hubfs/accencio-target-of-the-month-il17-2.jpg?width=1200&height=627&name=accencio-target-of-the-month-il17-2.jpg)](https://youtu.be/GDVdYI6e0n4?si=4qVDy8iAtyqkp3EE)Interleukin-17 (or IL17) is a key member of a family of pro-inflammatory cytokines.   

It links T cell activation to neutrophil activation. Because of this, it can contribute to the progression of autoimmune diseases such as psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Blocking IL-17 from activating its receptor by use of specific antibodies has been shown to have a positive effect on these diseases.  This month's video provides overall highlights and things that immunologists, molecular biologists, and IP professionals may want to be aware of as you generate new antibodies.

Each month we use [Accencio’s](https://www.accencio.com/)flagship IP-GeoScape® product to highlight a biological target that currently looks to be of great interest for biopharma and AI drug discovery researchers. Although our focus will be on the intellectual property implications primarily for researchers, these highlights may also be of interest for attorneys and licensing professionals.

[IP-GeoScape](https://www.accencio.com/products/ip-geoscape), is a visual landscape of the molecular IP space representing any given chemical area. The visualization tool enables researchers to See IP Differently™. Please [contact us](https://www.accencio.com/contact) if you are interested in a demo or speaking with an IP-GeoScape expert about how we can help you.

Kevin Brogle (Ph.D.) is a co-founder and the scientific leader of Accencio and is responsible for the creation of the Accencio landscaping technology.

Share: [Share this page on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://insights.accencio.com/blog/target-of-the-month-interleukin-17) [envelope icon](mailto:?body=https://insights.accencio.com/blog/target-of-the-month-interleukin-17)

 

[Privacy Policy](https://www.accencio.com/legal/privacy)      |     [Investors](https://accencio.nthround.io/join/)     |     Copyright © 2025 Accencio, LLC - All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Kevin Brogle (Ph.D.)",
    "url" : "https://insights.accencio.com/blog/author/kevin-brogle-ph-d"
  },
  "dateModified" : "2025-02-04T22:24:51.918Z",
  "datePublished" : "2024-11-08T17:58:48.000Z",
  "headline" : "Target of the Month: Interleukin-17",
  "image" : [ "https://insights.accencio.com/hubfs/accencio-target-of-the-month-il17.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://insights.accencio.com/blog/target-of-the-month-interleukin-17",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://insights.accencio.com/hubfs/ACCENCIO_Logo_final%20with%20R-2.png"
    },
    "name" : "Accencio LLC"
  }
}
```

```json
{
  "@context" : "http://schema.org",
  "@type" : "Article",
  "author" : {
    "@type" : "Person",
    "name" : [ "Kevin Brogle (Ph.D.)" ]
  },
  "datePublished" : "2024-11-08T17:58:48+0000",
  "description" : "Target of the month: Interleukin-17 or IL17",
  "headline" : "Target of the Month: Interleukin-17",
  "image" : "https://6406556.fs1.hubspotusercontent-na1.net/hubfs/6406556/accencio-target-of-the-month-il17.jpg",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://6406556.fs1.hubspotusercontent-na1.net/hubfs/6406556/ACCENCIO_Logo_final%20with%20R-2.png"
    },
    "name" : "Accencio LLC"
  },
  "url" : "https://insights.accencio.com/blog/target-of-the-month-interleukin-17"
}
```